Close Menu

NEW YORK (GenomeWeb) – Natera went public late last week, raising $180 million in an initial public offering on the Nasdaq Global Select Market.

The San Carlos, California-based reproductive health molecular diagnostics firm offered 10 million shares of common stock at an offering price of $18 per share. The underwriters on the offering — Morgan Stanley, Cowen and Co., Piper Jaffray, R.W. Baird, and Wedbush Securities — have an over-allotment option to purchase an additional 1.5 million shares.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.